| Primary |
| Metastatic Malignant Melanoma |
37.8% |
| Malignant Melanoma |
27.6% |
| Product Used For Unknown Indication |
13.7% |
| Prophylaxis |
4.3% |
| Hypertension |
3.1% |
| Pain |
2.0% |
| Thyroid Cancer |
1.5% |
| Nausea |
1.1% |
| Arthralgia |
1.0% |
| Hypothyroidism |
1.0% |
| Neoplasm Malignant |
1.0% |
| Back Pain |
0.9% |
| Constipation |
0.8% |
| Essential Hypertension |
0.8% |
| Headache |
0.7% |
| Neoplasm |
0.7% |
| Diarrhoea |
0.6% |
| Insomnia |
0.6% |
| Depression |
0.6% |
| Diabetes Mellitus |
0.5% |
|
| Disease Progression |
19.9% |
| Anaemia |
7.8% |
| Death |
7.1% |
| Squamous Cell Carcinoma Of Skin |
5.6% |
| Rash |
5.4% |
| Squamous Cell Carcinoma |
4.8% |
| Weight Decreased |
4.7% |
| Malignant Melanoma |
4.3% |
| Pyrexia |
4.1% |
| Dermatitis Exfoliative |
3.9% |
| Dyspnoea |
3.7% |
| Epilepsy |
3.5% |
| Renal Failure Acute |
3.5% |
| General Physical Health Deterioration |
3.4% |
| Pericarditis |
3.4% |
| Dehydration |
3.0% |
| Fatigue |
3.0% |
| Melanocytic Naevus |
3.0% |
| Pancreatitis |
3.0% |
| Pulmonary Embolism |
3.0% |
|
| Secondary |
| Prophylaxis |
23.9% |
| Metastatic Malignant Melanoma |
20.3% |
| Malignant Melanoma |
19.0% |
| Essential Hypertension |
8.5% |
| Insomnia |
4.7% |
| Diarrhoea |
4.5% |
| Thyroid Cancer |
4.5% |
| Thyroidectomy |
2.7% |
| Hypertension |
2.6% |
| Product Used For Unknown Indication |
2.5% |
| Nausea |
0.9% |
| Hypercholesterolaemia |
0.8% |
| Metastases To Central Nervous System |
0.7% |
| Pain |
0.7% |
| Abdominal Pain Lower |
0.6% |
| Coronary Artery Disease |
0.6% |
| Headache |
0.6% |
| Hypothyroidism |
0.6% |
| Neoplasm Malignant |
0.5% |
| Papillary Thyroid Cancer |
0.5% |
|
| Rash Erythematous |
11.2% |
| Hypotension |
7.4% |
| Rash |
7.4% |
| Squamous Cell Carcinoma Of Skin |
7.2% |
| Rash Macular |
6.9% |
| Anaemia |
5.2% |
| Dermatitis Exfoliative |
5.2% |
| Alanine Aminotransferase Increased |
4.9% |
| Blood Creatinine Increased |
4.6% |
| Malignant Melanoma |
4.3% |
| Pyrexia |
4.3% |
| Renal Failure |
4.0% |
| Weight Decreased |
4.0% |
| Pancreatitis |
3.7% |
| Squamous Cell Carcinoma |
3.7% |
| Headache |
3.4% |
| Cellulitis |
3.2% |
| Dehydration |
3.2% |
| Epilepsy |
3.2% |
| Hepatotoxicity |
3.2% |
|
| Concomitant |
| Product Used For Unknown Indication |
42.9% |
| Malignant Melanoma |
21.4% |
| Metastatic Malignant Melanoma |
21.4% |
| Deep Vein Thrombosis |
7.1% |
| Neoplasm |
7.1% |
|
| Adverse Drug Reaction |
10.0% |
| Death |
10.0% |
| Malignant Melanoma |
10.0% |
| Metastatic Malignant Melanoma |
10.0% |
| Rash Generalised |
10.0% |
| Renal Failure |
10.0% |
| Respiratory Disorder |
10.0% |
| Sinus Disorder |
10.0% |
| Spinal Cord Compression |
10.0% |
| Thrombocytopenia |
10.0% |
|
| Interacting |
| Product Used For Unknown Indication |
61.1% |
| Malignant Melanoma |
15.6% |
| Metastatic Malignant Melanoma |
14.4% |
| Oral Candidiasis |
5.6% |
| Pain |
2.2% |
| Nervous System Disorder |
1.1% |
|
| Overdose |
21.7% |
| Cholestasis |
13.0% |
| Drug Interaction |
13.0% |
| Pyrexia |
13.0% |
| Alanine Aminotransferase Increased |
8.7% |
| Fall |
8.7% |
| Neutropenia |
8.7% |
| Blood Alkaline Phosphatase Increased |
4.3% |
| Chronic Obstructive Pulmonary Disease |
4.3% |
| Condition Aggravated |
4.3% |
|
